Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$151.33K$151.33Kderived+786.7% vs Q4 2019 Net Income-$1.20M-$1.20MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,220,018N/M Operating Cash Flowderived-$953,660N/M Margins · derivedOperating margin-806.2%+6429.6 pt vs Q4 2019
Net margin-793.0%+6064.2 pt vs Q4 2019
ended Dec 31, 2020 · filed Mar 16, 2021 · 75 d after period end